Skip to main content

ChemT Biotechnology

Category: AI in Biotech / Drug Discovery

ChemT Biotechnology builds an AI-driven virtual cell platform (CelMo™) that optimizes biologics manufacturing by understanding, predicting, and modulating cell behavior for pharmaceutical production. ChemT Biotechnology was founded in 2024. The company is led by Jie Sun. Based in Singapore, Singapore. Team size: 2-10. Total funding raised: $5M. Latest round: Seed. Key investors include Wavemaker Ventures, SEEDS, Wavemaker 360 Health, Draper University Ventures, Temasek Life Sciences Accelerator, AIN Ventures, Arben Ventures, The Ignition AI Accelerator, BioTools Innovator, MedTech Innovator.

Founded
2024
Headquarters
Singapore, Singapore
Team size
2-10
Total funding
$5M

Value proposition

AI-powered virtual cell platform that brings intelligence directly into biomanufacturing, enabling pharmaceutical companies to understand, predict, and control cell behavior during biologics production — resulting in faster development, higher yields, and lower costs.

Products and solutions

CelMo™ (AI-driven virtual cell platform for biomanufacturing), Chemplify™ (AI-designed small molecule for T-cell manufacturing), AI-designed solutions for cell state modulation in CHO cells, T cells, stem cells, NK cells, HEK cells

Unique value

ChemT builds the AI layer for CMC (Chemistry, Manufacturing & Controls) — unlike conventional AI drug discovery companies that focus on finding new molecules, ChemT focuses on the manufacturing bottleneck itself, using its CelMo™ virtual cell platform to simulate, predict, and optimize how cells behave during production, achieving up to 50% faster development and 10x higher cell yields.

Target customer

Pharmaceutical and biotechnology companies involved in biologics manufacturing, cell and gene therapy development, and antibody/protein production

Industries served

Biologics manufacturing, Cell and gene therapy, Pharmaceutical biomanufacturing

Technology advantage

Proprietary AI virtual cell platform (CelMo™) trained on proprietary biological sequencing data and validated through wet-lab experiments; Demonstrated 50% increase in antibody output, 40% reduction in production timelines for CHO cells; Chemplify™ shows 50% faster development, 3x scalability, 60% lower costs, 10x higher cell expansion yield

How they differentiate

First company to build an AI intelligence layer directly into biomanufacturing CMC processes (not just drug discovery). CelMo™ virtual cell platform is trained on proprietary biological sequencing data and validated through lab experiments, enabling predictive cell behavior modeling for manufacturing optimization.

Main competitors

Cradle Bio, Cellino, Unicorn Bioscience

Key partnerships

Eli Lilly TuneLab (AI/ML innovation platform member), NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT), CARsgen Therapeutics (strategic partnership for cell therapy)

Notable customers

CARsgen Therapeutics (strategic partnership), Eli Lilly (via TuneLab membership)

Major milestones

Founded Oct 2024, Raised $5M total ($1M angel + $4M seed) within 18 months, NASDAQ Times Square Tower feature (Nov 2025), BioTools Innovator 2025 cohort, Joined Eli Lilly TuneLab, Joined NSF CMaT consortium, Strategic partnership with CARsgen Therapeutics, Won SMU Lee Kuan Yew Global Business Plan Competition, Co-founders named Prestige Singapore 40 Under 40 2026

Market positioning

Early-stage AI biomanufacturing company positioned at the intersection of AI and CMC (Chemistry, Manufacturing & Controls), targeting a critical underserved pain point in pharma — biologics manufacturing efficiency. Differentiating from conventional AI drug discovery companies by focusing on the manufacturing process itself.

Geographic focus

Global (Singapore HQ, US operations)

About Jie Sun

Ex-Co-Founder of Basys.ai (GenAI healthtech backed by Mayo Clinic & Eli Lilly); Data Science roles at Dana-Farber Cancer Institute & Mass General Hospital; Research published in The Lancet and AAAI; 40 Under 40 honoree by Boston Congress of Public Health; Forbes Business Council member; MS Health Data Science from Harvard University; BS Statistics from National University of Singapore

Official website: